ROIV Stock — Roivant Sciences Ltd.: Cash, EV, Pipeline

What they do

Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter.

Source: 10-K FY2026 via SEC EDGAR

Share price

$41.56

Market cap

$30,049.6M

Cash

$4,207.6M

Enterprise value

$25,842.0M

Balance sheet

Cash	$4,207.6M
Debt	$0.0M
Net cash	$4,207.6M
Enterprise value	$25,842.0M
Basic shares	722.3M shares
Fully diluted shares	722.3M shares
Fully diluted market cap	$30,019.7M
Cash per share	$5.83
Quarterly burn	$270.5M
Cash runway	14.2 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-10.

Share structure

Common

722.3M

Pre-funded warrants

0.0M

Options

0.0M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

722.3M

Cap table as of 2026-06-30.

Price history

Loading ROIV daily closes…

Loading price history…

Next catalyst

brepocitinib · Est. Nov 11, 2026 · half midpoint · guided Now

Recently reported

IMVT-1402 Positive · 2026-09-23

Source release →

mosliciguat Positive · 2026-09-08

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 11, 2026 Now half midpoint	brepocitinib Phase 3 study in non-infectious uveitis (NIU)	Phase 3	non-infectious uveitis (NIU)	2H 2026

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

IMVT-1402

Stage not disclosed · Active Modality: monoclonal antibody

Target FcRn

Partnerships HanAll Biopharma: core IP rights via the HanAll Agreement (Immunovant subsidiary)

Indications

Graves' disease (GD) (Stage not disclosed)
Difficult-to-treat rheumatoid arthritis (D2T RA) (Stage not disclosed)
Lichen planopilaris (LPP) (Stage not disclosed)

Status note Anti-FcRn antibody; the company's lead development program following discontinuation of batoclimab. Trials ongoing in D2T RA and other indications; filing references a potential launch in Graves' disease. No trial phase stated in the provided excerpts.

Brepocitinib

Phase 3 · Active Modality: small molecule

Target TYK2/JAK1

Partnerships Priovant (Roivant Vant); originally developed by Pfizer (other brepocitinib studies conducted by Pfizer)

Indications

Dermatomyositis (DM) (Phase 3)
Lichen planopilaris (LPP) (Phase 3)
Cutaneous sarcoidosis (CS) (Phase 2)

Catalysts

— None
— None
— None

Status note Oral TYK2/JAK1 inhibitor. FDA accepted the NDA in DM with Priority Review (target action date Q3 2026). Seamless Phase 2b/3 potentially registrational trial in LPP enrolled first subjects. Breakthrough Therapy Designation for cutaneous sarcoidosis (Phase 2 BEACON study complete).

Batoclimab

Phase 2 · Terminated Modality: monoclonal antibody

Target FcRn

Partnerships HanAll Biopharma: HanAll Agreement

Status note The company discontinued further development of batoclimab across all indications to focus fully on IMVT-1402.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Perceptive Advisors	8,085,461	-200,000	4.44%	2026-08-14
Baker Bros. Advisors	4,716,831	-150,892	0.84%	2026-08-14
ADAR1 Capital Management	3,157,008	-128,898	5.25%	2026-08-14
Cormorant Asset Management	475,000	-275,000	0.86%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ROIV — Roivant Sciences Ltd. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Specialist fund holders

Latest news

ROIV — Roivant Sciences Ltd.